Green zone Gastroenteroloji / Birinci Basamak

Irritable Bowel Syndrome — Diagnosis and Management

Irritable bowel syndrome is a functional bowel disorder that cannot be explained by a structural disease, characterized by recurrent abdominal pain related to defecation and a change in bowel habits. It is common in the population and significantly affects quality of life.

THE MOST IMPORTANT CONCEPT IS THIS: irritable bowel syndrome is not a diagnosis of EXCLUSION, it is a POSITIVE DIAGNOSIS. In a patient who meets the Rome criteria, has no alarm signs, and is of appropriate age, the diagnosis is made clinically; putting the patient through extensive investigations is both unnecessary and undermines trust by reinforcing the perception that 'nothing serious was found.' On the other hand, a LIMITED and TARGETED initial evaluation is necessary: complete blood count, C-reactive protein or fecal calprotectin, and CELIAC SEROLOGY.

These tests help distinguish inflammatory bowel disease and celiac disease in diarrhea-predominant presentations, both of which can mimic irritable bowel syndrome. In the presence of ALARM SIGNS (rectal bleeding, unintentional weight loss, symptoms that wake the patient at night, new onset after age fifty, family history of colorectal cancer or inflammatory bowel disease, iron deficiency anemia), the diagnosis is not considered irritable bowel syndrome and further investigation is required.

Treatment is tailored according to the subtype (diarrhea-predominant, constipation-predominant, mixed) and the dominant symptom; the quality of the patient-physician relationship is one of the determinants of treatment success.

Rapid management

If there are no alarm signs, make a positive diagnosis using Rome criteria; assess the likelihood of celiac/IBD with limited targeted tests, and personalize treatment according to stool subtype.

Drug	Adult	Pediatric	Route	Duration
Positive diagnosis: Rome criteria + absence of alarm signs Understanding that irritable bowel syndrome is not a diagnosis of exclusion is the most important conceptual step in managing this disease. The diagnosis is based on the presence of a specific symptom pattern and the absence of alarm signs; that is, the physician does not try to prove that something is not present, but recognizes what is there. This approach has two practical consequences. First, there is no need for an extensive series of tests in an appropriate patient; colonoscopy, abdominal CT, and numerous blood tests are normal in most patients and do not contribute to the diagnosis. Second and more importantly, the exclusion approach distorts the patient's perception of illness: telling the patient 'we didn’t find anything' after repeatedly normal tests creates the impression that their complaints are not taken seriously or that a diagnosis cannot be made. However, the disease has a name, its diagnostic criteria are clear, and treatment is available. Clearly establishing the diagnosis and telling the patient its name forms the basis of the treatment relationship.	Presence of recurrent abdominal pain related to defecation along with changes in stool frequency and/or consistency; the duration and frequency of symptoms are assessed using Rome criteria (exact thresholds should be verified from the current Rome version)	Separate pediatric functional bowel disorder criteria are used in children; growth delay and alarm signs should be excluded	—	At the time of diagnosis
Limited and targeted initial testing The principle of limited testing does not mean performing no tests at all; the goal is to differentiate between two diseases that mimic irritable bowel syndrome and have completely different treatments. The first of these is inflammatory bowel disease: fecal calprotectin is a non-invasive indicator reflecting intestinal inflammation, and when found to be low, it significantly reduces the likelihood of inflammatory bowel disease, thereby also reducing the need for colonoscopy. The second is celiac disease; the prevalence of celiac disease in patients diagnosed with irritable bowel syndrome is higher than in the general population, and serological screening is cheap, easy, and high-yield. An irritable bowel syndrome diagnosis made without performing these two tests carries the risk of missing two treatable diseases. On the other hand, if these tests are normal and there are no alarm signs, further imaging and endoscopy are unnecessary for most patients.	Complete blood count, C-reactive protein, and/or FECAL CALPROTECTIN, CELIAC SEROLOGY (tTG-IgA + total IgA). Particularly necessary in diarrhea-dominant presentations	In children, growth parameters are also evaluated alongside the same tests	—	Diagnostic evaluation
Screening for alarm signs Alarm symptoms are a safety net that must be queried before making a functional diagnosis. Among these, the most commonly overlooked is the symptom waking the patient at night; in functional bowel diseases, complaints typically occur while awake and do not disrupt sleep; therefore, pain or diarrhea that wakes the patient at night suggests an organic cause. The age of onset is also important: a change in bowel habits beginning for the first time in older age requires an organic cause until proven otherwise, and colorectal cancer is at the top of the differential diagnosis in this age group. Iron deficiency anemia may reflect hidden blood loss or a malabsorption disease such as celiac disease. Family history changes risk for both colorectal cancer and inflammatory bowel disease. If any of these symptoms are present, a diagnosis of irritable bowel syndrome is not made; the patient is referred to the appropriate diagnostic pathway.	Rectal bleeding, involuntary weight loss, pain or diarrhea that wakes the patient at night, new symptoms starting after the age of fifty, a family history of colorectal cancer or inflammatory bowel disease, iron deficiency anemia, palpable mass, and fever are questioned. IF PRESENT, the diagnosis is not irritable bowel syndrome	In children, growth retardation, delayed puberty, perianal disease, and recurring fever are also alarm signs	—	At each assessment
Explaining the diagnosis and establishing its relationship with treatment This step is not an optional addition to the treatment but a directly effective component. Patients with irritable bowel syndrome often go through years of their complaints not being taken seriously, being labeled as "stress" or "imagination"; this experience both increases the disease burden and undermines trust in the physician. Clearly stating the diagnosis and affirming that the disease is a real disorder breaks this cycle. Two components of the explanation are particularly important. The first is explaining the mechanism: it should be noted that there are changes in communication between the gut and the central nervous system and in gut sensitivity, meaning that the complaints have a real physiological basis. The second is providing reassurance: most patients have concerns about cancer or a progressive disease; it should be clearly stated that this disease does not cause structural damage and does not turn into cancer. These two statements also significantly reduce unnecessary requests for tests.	The diagnosis is told to the patient by name; it is clearly explained that the complaints are REAL, arise from changes in the gut-brain axis and gut sensitivity, but do not cause STRUCTURAL DAMAGE and DO NOT TURN INTO CANCER	The same explanation is given to the child and family in age-appropriate language; school absenteeism and anxiety are also addressed separately	—	At diagnosis and follow-up
Treatment according to subtype and dominant complaint Treatment is shaped not according to a single scheme but according to the patient’s dominant complaint; therefore, determining the subtype is the first step in treatment selection. In constipation predominant cases, soluble fiber (especially psyllium type) is the first step; it should be kept in mind that insoluble fiber (like bran) may worsen complaints by increasing bloating. In diarrhea predominant cases, options that slow bowel transit are used. When pain and bloating are predominant, antispasmodics may provide short-term benefit; peppermint oil is also considered in this group. In patients with resistant complaints, effective treatments through the gut-brain axis (low-dose antidepressants) and psychological approaches (cognitive-behavioral therapy, gut-directed hypnotherapy) are effective; this does not mean that the disease is "psychological"—they are used because they alter gut sensitivity and pain perception, and this distinction should be clearly explained to the patient.	The SUBTYPE is determined (diarrhea predominant, constipation predominant, mixed) and the treatment is chosen accordingly. For constipation predominant, soluble fiber and appropriate laxatives; for diarrhea predominant, options that slow bowel movement; for pain predominant, antispasmodics and gut-brain axis therapies. AGENT AND DOSES must be verified from institutional protocols and current guidelines	In children, treatment is planned with pediatric gastroenterology; drug options are limited and behavioral approaches come to the forefront	PO	According to response; regular review
Dietary approach — trial of a low FODMAP diet The low FODMAP diet is based on reducing fermentable short-chain carbohydrates and reduces bloating and pain in a significant portion of patients. However, this diet is not designed as a permanent lifestyle and its indefinite application is undesirable: it narrows dietary diversity, limits social life, and may have unwanted effects on gut microbiota. Proper use is in three phases: time-limited restriction, assessment of response, and then gradual reintroduction of foods to determine the patient's own threshold. Since this process requires detail, conducting it under the guidance of a dietitian increases both efficacy and safety. Before starting the diet trial, celiac serology should be obtained; celiac tests become misleading under a restrictive diet.	It begins with general measures (regular meals, avoidance of excessive caffeine/alcohol and fatty foods). In patients who do not respond, a LOW FODMAP diet is applied as a TRIAL, preferably under the guidance of a DIETITIAN, and if a response is obtained, it is personalized with gradual reintroduction.	In children, restrictive diets are applied only under the supervision of a dietitian and for a limited duration due to growth risk.	Diet	The trial period is limited; if a response is obtained, reintroduction is performed.

Alternative

In constipation-predominant cases, when soluble fiber is insufficient, osmotic laxatives and secretagogues are considered; the choice of agent and reimbursement conditions are determined according to institutional protocol.
In diarrhea-predominant cases, bile acid diarrhea is included in the differential diagnosis, and response to bile acid-binding treatment may be a diagnostic clue; a history of cholecystectomy increases this possibility.
In bloating and gas-predominant cases, small intestinal bacterial overgrowth should be considered; in appropriate cases, testing and targeted treatment are evaluated.
In resistant cases, low-dose antidepressants effective via the gut-brain axis are used (tricyclics in diarrhea-predominant, selective serotonin reuptake inhibitors in constipation-predominant); in this preference, the effect of the drug on gut transit is decisive.
Psychological treatments (cognitive-behavioral therapy, gut-directed hypnotherapy) are proven options and do not imply that the disease is psychological; they can be offered early when accessible.
Some probiotics have reported benefits in bloating and general complaints; strains and duration are not standardized, trials are conducted for a period, and if no benefit is observed, they are not continued.
Peppermint oil may provide short-term relief for pain and bloating; it should be noted that it may increase reflux symptoms.

Red flags

RECTAL BLEEDING or positive fecal occult blood → irritable bowel syndrome should not be diagnosed; colorectal pathology should be investigated.
UNINTENTIONAL WEIGHT LOSS → evaluation for organic disease, malignancy, and malabsorption is required.
Pain or diarrhea that wakes the patient at NIGHT → not expected in functional disease; suggests an organic cause.
Change in bowel habits starting after the FIFTIES → colorectal cancer should be primarily excluded.
IRON DEFICIENCY ANEMIA → hidden bleeding or malabsorption such as celiac disease should be investigated (relevant protocols).
Family history of COLORECTAL CANCER or INFLAMMATORY BOWEL DISEASE → the diagnostic threshold should be lowered, and further investigation should be considered.
FEVER, palpable MASS or elevated acute phase reactants → inflammatory or infectious causes should be investigated.
Completely omitting CELIAC SEROLOGY → a treatable and mimicking disease may be overlooked.
Starting a restrictive diet without obtaining celiac serology → subsequent celiac tests become misleading.
Long-term OPIOID use → narcotic bowel syndrome may develop and paradoxically increase pain; it should be avoided.

Disposition and follow-up

Green zone: Patient meeting Rome criteria with no alarm signs: outpatient diagnosis and treatment, limited initial tests, explanation of diagnosis, treatment according to subtype, and planned outpatient follow-up.
Yellow zone: Treatment-resistant symptoms, significant quality of life loss, diagnostic uncertainty, or accompanying psychiatric burden: gastroenterology evaluation, targeted planning of advanced tests, and multidisciplinary treatment.
Red zone: Presence of alarm signs (bleeding, weight loss, fever, mass), severe dehydration, or acute abdomen findings: move away from irritable bowel syndrome diagnosis, proceed with urgent evaluation and relevant protocols.

Key clinical points

READ FIRST — this is not a DIAGNOSTIC EXCLUSION

Irritable bowel syndrome is a POSITIVE DIAGNOSIS: It is clinically made in a patient who meets the Rome criteria + has NO ALARM SYMPTOMS | Extensive testing (colonoscopy, abdominal CT, numerous blood tests) comes out NORMAL in most patients and does not contribute to the diagnosis | WORSE: saying "we didn't find anything" after consecutive normal tests creates the perception that the patient's complaints are not taken seriously and undermines trust | The disease has a NAME, CRITERIA, and TREATMENT — make the diagnosis and state it by name

This conceptual distinction directly determines both the patient's diagnostic burden and illness experience. A physician who approaches with an exclusion logic tries to eliminate organic diseases in sequence and moves to the next test after each normal result; this process can take months, is costly, and the only thing that can eventually be told to the patient is what is not present. However, irritable bowel syndrome has defined symptom criteria, and in a patient who meets these criteria and has no alarm symptoms, the diagnosis can be made directly. This approach not only prevents unnecessary tests but also provides the patient with a concrete diagnosis and treatment plan. Most patients come with a history where their complaints were labeled as "stress" or "imaginary" for years; this experience increases the disease burden. Clearly making the diagnosis, explaining the mechanism, and stating that the disease is real is the first and most effective step in treatment.

READ FIRST — limited testing does not mean no testing at all

MANDATORY minimum set: complete blood count + C-reactive protein and/or FECAL CALPROTECTIN + CELIAC SEROLOGY (tTG-IgA + total IgA) | REASON: two diseases can mimic this picture and their treatments are completely different — INFLAMMATORY BOWEL DISEASE and CELIAC | If fecal calprotectin is low, the likelihood of IBS significantly decreases → need for colonoscopy also decreases | Celiac is more common in patients diagnosed with IBS than in the general population; the test is cheap and highly informative | WARNING: obtain celiac serology BEFORE starting a restrictive diet

The principle of limited investigation is easily misunderstood and is sometimes applied as not conducting any investigation at all; this leads to the oversight of two treatable diseases. The aim is not to reduce investigation but to make it targeted. Inflammatory bowel disease and celiac disease present symptoms that overlap with irritable bowel syndrome, and especially in diarrhea-predominant cases, clinical differentiation is not possible. Fecal calprotectin is a non-invasive marker reflecting intestinal inflammation; when found to be low, the likelihood of inflammatory bowel disease decreases significantly, and this information allows many patients to avoid colonoscopy. Celiac serology, on the other hand, is inexpensive, easily accessible, and highly informative. There is a critical sequencing detail: if a restrictive diet (especially low FODMAP or gluten-free) is to be recommended to the patient, celiac serology should be obtained before this diet because when gluten intake decreases, the test becomes misleading.

READ FIRST — alarm signs: the most commonly missed is "night awakening"

RECTAL BLEEDING · UNINTENTIONAL WEIGHT LOSS · PAIN/DIARRHEA THAT WAKES THE PATIENT AT NIGHT · NEW ONSET AFTER FIFTIES · FAMILY HISTORY OF COLORECTAL CANCER or IBD · IRON DEFICIENCY ANEMIA · PALPABLE MASS · FEVER | MOST COMMONLY MISSED: in functional disease, symptoms occur while the patient is awake and DO NOT INTERRUPT SLEEP — pain or diarrhea that wakes at night suggests an ORGANIC cause | If any of these are present, the diagnosis IS NOT IBS; proceed to the relevant diagnostic pathway

Alarm signs are a safety checkpoint that must be passed before establishing a functional diagnosis and should be reassessed at every evaluation, as new symptoms may appear during the course of the disease. The item most frequently overlooked on this list is whether the symptoms wake the patient at night. In functional bowel diseases, symptoms typically occur during the day while the patient is awake and do not disturb sleep; this observation is a pattern explained via the gut-brain axis. In contrast, abdominal pain or diarrhea that wakes the patient at night suggests a structural or inflammatory cause and necessitates re-evaluation of the diagnosis. Age at new onset is also decisive: a change in bowel habits first appearing at an older age is considered organic until proven otherwise, and colorectal cancer is at the top of the differential diagnosis for this age group. Iron deficiency anemia may indicate both occult bleeding and malabsorption.

Low FODMAP: a temporary TRIAL, not a permanent lifestyle.

Used in THREE STAGES: (1) SHORT-TERM restriction, (2) response evaluation, (3) gradual REINTRODUCTION to find the patient's own threshold | INDEFINITE application is HARMFUL: narrows the variety of nutrition, restricts social life, may have unwanted effects on the microbiota | Conducting under the supervision of a DIETITIAN increases both effectiveness and safety | In CHILDREN, restrictive diets should only be applied under supervision and for a limited time due to the risk to growth

The low FODMAP diet is based on reducing fermentable short-chain carbohydrates and provides benefit for a significant portion of patients particularly in terms of bloating and pain. However, a common mistake in clinical practice is maintaining the diet as a permanent restriction. This has two drawbacks. The first is related to nutrition: since the diet restricts many fruits, vegetables, grains, and dairy products, long-term use narrows nutritional variety and intake of certain nutrients may be insufficient; also, unwanted effects on the gut microbiota have been reported. The second concern is related to quality of life: a wide restriction list makes eating out and social situations difficult and may reduce the patient’s quality of life regardless of symptoms. Correct use is to keep the restriction for a limited time and, if a response is achieved, gradually reintroduce foods to determine the patient's own tolerance threshold.

Things to avoid and common mistakes

LONG-TERM OPIOID → narcotic bowel syndrome; paradoxically increases pain and creates dependency | REPEATED ANTIBIOTIC courses → disrupt the microbiota in non-evidence-based use | INSOLUBLE fiber like BRAN → can worsen bloating and symptoms (soluble fiber is preferred) | REPEATED COLONOSCOPY → does not contribute to diagnosis if there are no alarm symptoms, reinforces patient anxiety | Just saying 'stress' → it should be stated that the disease is real and the mechanism should be explained

This list gathers practices that are well-intentioned but harmful. Opioids seem appropriate for a patient describing severe abdominal pain; however, long-term use leads to a condition called narcotic bowel syndrome, in which pain paradoxically increases due to the medication itself, and additionally, the risk of addiction arises. The use of antibiotics without evidence and repeatedly disrupts the microbiota balance and provides no long-term benefit. In fiber recommendations, the type is important: soluble fiber (such as psyllium) is particularly beneficial in constipation-predominant conditions, while insoluble fiber like bran can worsen symptoms by increasing gas and bloating. Repeating a colonoscopy in a patient without alarm signs does not contribute to diagnosis and reinforces the patient's serious disease anxiety. Finally, dismissing symptoms by saying 'stress' is the most common and harmful approach; it should be clearly explained that the disease is real and has a defined mechanism.

Featured external sources

ACG IBS clinical guideline.Positive diagnosis, initial tests, and treatment options.
BSG IBS guideline.Alarm symptoms and long-term management.
AGA diet update for IBS.Principles of diet and low-FODMAP implementation.
Rome V clinical criteria.Current DGBI classification framework.

Detailed assessment

Diagnostic and decision reasoning

Clinical framework

Overview

Irritable bowel syndrome is a functional bowel disease characterized by recurrent abdominal pain related to defecation and changes in stool frequency and consistency, which cannot be explained by a structural disease. It is common in the population, more frequent in women, and its impact on quality of life is comparable to many organic diseases.

Its pathophysiology involves disruption in the gut-brain axis, visceral hypersensitivity, motility changes, increased mucosal permeability, low-grade inflammation, and microbiota alterations; in some patients, the condition begins after an infectious gastroenteritis. The most important concept regarding diagnosis is that this disease should be diagnosed positively rather than as a diagnosis of exclusion: in a patient who meets the Rome criteria, has no alarm signs, and is of appropriate age, the diagnosis is made clinically.

Nevertheless, a limited and targeted initial evaluation is necessary; complete blood count, C-reactive protein or fecal calprotectin, and celiac serology help distinguish inflammatory bowel disease and celiac disease, which mimic the condition but have entirely different treatments. In the presence of alarm symptoms, a diagnosis of irritable bowel syndrome is not made, and the patient is directed to the relevant diagnostic pathway.

Treatment is shaped according to the subtype and dominant complaint; diet modification, fiber, targeted medications, and in resistant cases, psychological approaches using treatments effective through the gut-brain axis are used. Clearly explaining the diagnosis to the patient and stating that the disease is real is an integral and effective component of the treatment.

Differential diagnosis and assessment

Key considerations

Celiac disease is seen more frequently in the population among patients diagnosed with irritable bowel syndrome and causes similar complaints; serological screening is a mandatory part of the diagnostic process (relevant protocol).
Inflammatory bowel disease, especially in diarrhea-dominant presentations, is at the forefront of differential diagnosis; stool calprotectin and acute-phase response help in differentiation (relevant protocol).
Microscopic colitis is a condition characterized by watery diarrhea and macroscopically normal appearance on colonoscopy; diagnosis is made with biopsy and should be considered particularly in older patients with diarrhea-dominant cases.
Bile acid diarrhea occurs after cholecystectomy or idiopathically and mimics a diarrhea-dominant presentation; response to bile acid binding therapy can be a diagnostic clue.
Small intestinal bacterial overgrowth is part of the differential diagnosis in bloating and gas-dominant presentations and may be associated with underlying motility disorder or surgical history.
Lactose and fructose intolerance cause similar bloating and diarrhea complaints; dietary history and elimination trial are distinguishing factors.
Colorectal cancer should be primarily excluded, especially in older age with newly onset changes in bowel habits and the presence of alarm symptoms (relevant protocol).
Endometriosis can cause pain related to the cycle and bowel complaints and is an often overlooked differential diagnosis in female patients.
Chronic pancreatitis and pancreatic exocrine insufficiency should be considered when accompanied by fatty stools and weight loss (relevant protocol).
Drug-related bowel complaints (metformin, magnesium-containing drugs, opioids, non-steroidal anti-inflammatory drugs) are frequently overlooked and do not appear without questioning the medication history.

Clinical decision reasoning

Why it matters

In the management of irritable bowel syndrome, what determines the clinical outcome is the way the diagnosis is made, rather than advanced investigations. Considering this disease as a positive diagnosis solves three problems at once.

The first is the burden of testing: when approached with an exclusion logic, the patient enters a long chain of tests, which is costly and ultimately provides information only on what is not present. The second is the perception of the disease, which is even more important: after consecutive normal results, telling the patient 'we didn’t find anything' creates the impression that their symptoms are not taken seriously or that the physician cannot make a diagnosis; whereas the patient has a defined disease and it can be treated.

The third is that unnecessary tests can themselves cause harm; incidental findings lead to new investigations and reinforce patient anxiety. On the other hand, the principle of limited testing also causes harm when applied as doing no tests at all.

Therefore, the concept of the minimal set is important: inflammatory bowel disease and celiac disease clinically overlap with irritable bowel syndrome, and their treatments are completely different. Fecal calprotectin and celiac serology largely distinguish these two diseases due to being inexpensive and noninvasive, and eliminate the need for colonoscopy in many patients.

Screening for alarm symptoms is the safety net and should be repeated in every assessment, because new symptoms may appear during the course of the disease. Among these symptoms, the most frequently overlooked is that symptoms wake the patient at night; in functional bowel diseases, symptoms occur while awake and do not disturb sleep, so pain or diarrhea that wakes the patient at night requires reassessment of the diagnosis.

The most common mistake on the treatment side is approaching the disease only with medication. Explaining the diagnosis and acknowledging the reality of the disease carries a measurable therapeutic effect; most patients come with a history in which their symptoms were underestimated for years, and this experience increases both the disease burden and the use of healthcare services.

On the dietary side, the low FODMAP approach should be positioned as a temporary trial; permanent restriction narrows dietary variety and reduces quality of life independently of the symptoms. Finally, applications that should be avoided must be particularly emphasized because they are done with good intentions: long-term opioid use leads to narcotic bowel syndrome, paradoxically increasing pain, repeated courses of antibiotics are not evidence-based, and insoluble fiber can worsen bloating.

Safety and monitoring

Complications and safety

Critical complications

Significant decrease in quality of life, loss of workforce, and school absenteeism are the most important outcomes of the disease and can be comparable to organic diseases.
Anxiety disorder and depression can accompany the disease and increase the severity of complaints; there is a mutual interaction through the gut-brain axis.
Unnecessary and repeated tests lead to new examinations through incidental findings and increase patient anxiety.
Maintaining restrictive diets for a long time narrows nutritional diversity, can leave the intake of some nutrients insufficient, and restricts social life.
Long-term opioid use leads to narcotic bowel syndrome; in this condition, pain increases due to the medication and the risk of addiction emerges.
Laxative abuse can cause electrolyte disturbances and impaired bowel function in constipation-dominant cases.
Not disclosing the diagnosis and downplaying the complaints harms the patient-doctor relationship, increases doctor-changing behavior, and increases health service utilization.
Accompanying functional disorders (fibromyalgia, chronic fatigue, functional dyspepsia) are common and increase the total symptom burden.

Special patient populations

Special considerations

Pediatric functional bowel disease criteria are used in children and adolescents; growth retardation, delayed puberty, perianal disease, and recurrent fever are alarm signs, and restrictive diets are applied only under supervision.
In first-onset symptoms at advanced age, the diagnosis of irritable bowel syndrome is made cautiously; colorectal cancer, microscopic colitis, and drug-related causes should be excluded first.
Symptoms may vary during pregnancy; drug options are limited, and treatment is planned with emphasis on diet and behavioral approaches.
Cases starting after infectious gastroenteritis form a separate subgroup; in these patients, symptoms may regress over time and this information should be conveyed to the patient.
In a patient who has undergone cholecystectomy, bile acid diarrhea stands out in the differential diagnosis in a diarrhea-dominant pattern.
In patients with comorbid anxiety disorder or depression, gut-brain axis therapies and psychological approaches can be introduced at an earlier stage; this preference does not mean that the disease is psychological.
In patients diagnosed with celiac disease or inflammatory bowel disease, persistent complaints may be due to overlapping irritable bowel syndrome even if the disease is in remission, and this distinction prevents unnecessary increase in immunosuppression.

Follow-up and reassessment

Follow-up plan

The purpose of follow-up is to assess treatment response, rescreen for alarm symptoms, and maintain the treatment relationship. After diagnosis, the first follow-up is planned at an interval sufficient to observe the effect of the chosen treatment; the response should be evaluated not only by the severity of complaints but also in terms of quality of life and daily functionality.

Alarm symptoms should be reassessed at each follow-up; rectal bleeding, weight loss, nocturnal symptoms, or anemia emerging during the course of the disease require a re-evaluation of the diagnosis. In patients undergoing a dietary trial, the duration of restriction and whether the reintroduction phase has been started should be specifically questioned; patients applying indefinite restriction should be referred to a dietitian.

In patients receiving drug treatment, efficacy and side effects are reviewed; drugs that do not provide benefit are not continued. If long-term opioid use is detected, a reduction plan should be made, and the possibility of narcotic bowel syndrome should be explained to the patient.

In patients using laxatives, the dose and frequency as well as electrolyte status are monitored. In resistant cases, gut-brain axis therapies and psychological approaches should be considered; it should be clearly explained that such approaches do not mean that the disease is psychological, but are used because they alter gut sensitivity and pain perception.

Comorbid anxiety disorder and depression should be screened, and patients should be directed to appropriate support if necessary. The patient should be informed that symptoms may have a fluctuating course, flare-up periods can be expected, and this does not indicate treatment failure; this information reduces unnecessary visits and anxiety.

Eligibility for colorectal cancer screening programs should also be evaluated according to age; an irritable bowel syndrome diagnosis does not eliminate the need for age-appropriate screening.